



Tegsedi in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

RARE DISEASE · HATTR POLYNEUROPATHY

The clinical situation

Tegsedi (inotersen) is a subcutaneous antisense oligonucleotide that reduces hepatic TTR production, FDA-approved for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Manufactured by Akcea/Ionis. Administration is a 284 mg subcutaneous injection weekly via a single-dose syringe. Tegsedi carries REMS-level risks of thrombocytopenia and glomerulonephritis requiring weekly platelet monitoring and every-two-week urine protein/creatinine ratio. Pre-treatment workup covers TTR genotype, vitamin A supplementation counselling, and full baseline renal/platelet workup per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist documents hATTR polyneuropathy diagnosis, TTR genotype, platelet and renal baseline, and Tegsedi rationale.
- 2 Baseline workup.** Vitamin A counselling, platelet count, UPCR, LFTs; weekly and bi-weekly monitoring plan per FDA REMS.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, monitoring plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with cold-chain 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the weekly pre-filled syringes; subcutaneous administration arranged with the treating physician.

Indicative economics

Reference US cash-pay range: USD 390,000–430,000 per year of Tegsedi (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Akcea/Ionis authorised distribution.

Documentation. Physician kit tailored to MoHAP review, with platelet and renal monitoring REMS-equivalent annex.

Logistics. Cold-chain 2–8°C internationally tracked shipment with temperature excursion log. **Concierge case lead.** Named point of contact for family and physician through weekly dosing cadence. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Tegsedi × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/tegsedi-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team